ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come? | Zendy

Martin Fishman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come?

Author(s) -

Martin Fishman

Publication year - 2004

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2004/862152

Subject(s) - medicine , celecoxib , rofecoxib , colorectal cancer , colorectal adenoma , adenoma , incidence (geometry) , medical prescription , gastroenterology , cancer , nonsteroidal , oncology , general surgery , cyclooxygenase , pharmacology , biochemistry , chemistry , physics , optics , enzyme

This paper described a nested case-control study on all Quebec patients over 65 years of age who underwent total colonic imaging or surgery for colorectal cancer (CRC) during a specified six-month period without similar testing in the preceding year. Information from the provincial government database was collected for each subject to estimate the consumption of prescription acetylsalicylic acid (ASA), standard nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2- specific inhibitors (coxibs) during the previous year. Of 2568 subjects, 730 were found to have at least one adenoma (but not carcinoma) and 129 were found to have CRC (with or without adenoma). Patients with and without adenoma or carcinoma were compared for type, amount and duration of drug exposure to determine if there was a protective effect. Rofecoxib and NSAIDs were associated with reduced incidence of colorectal adenoma (CRA), and these drugs and celecoxib protected against CRA and CRC

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research